Post Operative Sciatica by Lumbar Spinal Fibrosis
Conditions
Keywords
Sciatica, Pain, TNF-alpha, Discectomy, Fibrosis, Spine
Brief summary
TNF-alpha is the main cytokine implicated in the formation of lumbar spinal fibrosis. Inhibiting TNF-alpha could significantly decrease spinal fibrosis after lumbar discectomy.
Detailed description
OBJECT: Failed back surgery syndrome is still a challenging therapeutic problem. Clinical studies have demonstrated a significant association between lumbar spinal fibrosis after lumbar discectomy and the recurrence of radicular pain in 25% of cases. Forceful epidural infiltrations, radiotherapy, therapy with D-penicillamine or surgical procedures have had unfavourable results in terms of pain and cost. Magnetic resonance imaging reveals lumbar spinal fibrosis by a hyposignal in the T1 sequence and a hypersignal in T2 sequence around the spinal tissue. Tumor necrosis factor a (TNF-a) is the main cytokine implicated in the formation of tissue fibrosis. In animal models of fibrosis, TNF-a inhibition has been shown to prevent and treat tissue fibrosis. HYPOTHESIS: Inhibiting TNF-a could significantly decrease sciatica pain because of lumbar spinal fibrosis after lumbar discectomy by decreasing spinal fibrosis. METHODS: We propose a 2-year pilot prospective, randomized, double-blind, controlled study of TNF-a inhibitor (infliximab) in patients with sciatica as a result of postoperative lumbar spinal fibrosis. The infliximab group will receive one intravenous injection of 3 mg/kg infliximab. The control group will receive one physiological serum injection. Patients will be evaluated at day 0, 10, 30, 90, and 180. The main evaluation criterion will be sciatica pain as measured on a visual analog scale, with the objective of a 50% decrease in pain at day 10. This objective leads to a size of 20 patients per group. The other evaluation criteria will be clinical, functional, social, and professional. Patients will be recruited from the rehabilitation unit at Cochin teaching hospital.
Interventions
DRUGTNF blocker
Treatment with TNF-alpha blocker
DRUGPlacebo
Treatment with placebo
Sponsors
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age over 18 years old * sciatica post discectomy * Pain with VAS \> 40 mm and impossibility to have his usual activity * Surgical discectomy (less than 2 years and more than 6 months) * Painless of more than one month and less than one year after the discectomy * MRI with gadolinium injection of less than 6 months and done more than 6 months after the discectomy * Presence of spinal fibrosis on MRI (hyposignal in T1 enhanced by gadolinium and hypersignal in T2) * failure of epidural injection treatment * absence of tuberculosis * contraception for woman * informed consent
Exclusion criteria
* Chronic psychiatric pathologies not treated * Presence of conflict between nerve root and herniated disc or disc fragments or spinal stenosis * severe cognitives troubles * severe cardiac failure (class III or IV) * Tuberculosis (active or latent), severe infections * Cancers * Allergy reactions to the drug studied * Difficulties to understand french * Patients enrolled in another clinical trial in the past three months * pregnancy, breastfeeding or no contraception
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sciatica pain | 10 days after treatment | Visual analogue scale of lumbar pain |
Secondary
| Measure | Time frame |
|---|---|
| Functional assessments | At 10, 30, 90, 180 days |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORFrancois Rannou, MD, PhD
Assistance Publique - Hôpitaux de Paris
Outcome results
None listed